Guardant Health reports Shield test 83% sensitivity, 90% specificity for CRC in ECLIPSE study at DDW

Guardant Health, Inc.

Shield blood test achieved 83% overall sensitivity and 90% specificity in detecting colorectal cancer in average-risk adults.
Sensitivity of 55% for Stage I, 100% for Stages II, III, and IV; 81% for Stages I-III, 72% for localized (Stage I-II).
Real-world adherence rate for Shield exceeds 90% since commercial launch in May 2022.
Study enrolled diverse population: 13% Black, 15% Hispanic, 7% Asian American.
Data suggests Shield could detect CRCs at curable stage and help close screening gap.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.